- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Auth. number :||EU/2/13/148|
|Active substance :||Meloxicam|
|ATC:||Anatomical main group: QM - Musculo-skeletal system|
Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products
Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids
Chemical subgroup: QM01AC - Oxicams
Chemical substance: QM01AC06 - Meloxicam
(See WHO ATCvet Index)
|Indication:||Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. |
Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves.
Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For the relief of post-operative pain associated with minor soft tissue surgery such as castration. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic.
|Marketing Authorisation Holder:||Le Vet Beheer B.V.
Wilgenweg 7, NL-3421 TV Oudewater, Nederland
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|24/04/2013||Centralised - Authorisation||EMEA/V/C/2590||(2013)2397 of 22/04/2013|
|06/12/2013||Centralised - 2-Monthly update||EMEA/V/C/2590/IB/1||(2013)8832 of 03/12/2013|
|31/03/2015||Centralised - Variation||EMEA/V/C/2590/IAin/3|